斯奇康联合脱敏对哮喘缓解期患者血清IgE及IL-4的影响

Influnence of Siqikang with specific desensitization upon serum IgE and IL-4 of bronchial asthmatic patients during the remission

  • 摘要: 目的:探讨斯奇康(卡介菌多糖核酸:BCG-PSN)联合特异性脱敏(SIT)对哮喘缓解期患者血清IgE及IL-4的影响。方法:选择支气管哮喘缓解期患者90例,随机分为3组,分别给予斯奇康、特异性脱敏及斯奇康联合特异性脱敏治疗,并比较3组治疗后血清总IgE及IL-4的变化。结果:联合治疗组36 d后IL-4水平开始下降,疗程结束时显著降低(6.50±8.30)ng·L-1,与单用斯奇康组和特异性脱敏组比较差异显著(P<0.05);此时血清总IgE在一定程度上降低(261±329)mg·L-1结论:斯奇康与特异性脱敏联合治疗可减少体内炎性细胞因子释放,较单用斯奇康、脱敏治疗起效快。

     

    Abstract: Objective: To observe the influence of Siqikang(bacillus calmate guerin-polysaccharide nucleinic acid: BCG-PSN) combined specific desensitization(SIT) upon serum IgE and IL-4 of the bronchial asthmatic patients during the remission stage.Methods: 90 cases of the bronchial asthmatic patients during the remission stage were selected and randomly divided into three groups,to who respectively was given the treatment of Siqikang(BCG-PSN),SIT and Siqikang(BCG-PSN) combined SIT(conbined treatment group).The changes in serum IgE and IL-4 were compared between these 3 groups.Results: After 36 d treatment,IL-4 level of the patients in the combined treatment group started to decrease,and IL-4 level was significantly lower in 108 d(6.50±8.30)ng·L-1,there was a significant difference between the combined group and the other two groups(P<0.05),and there was a decrease in total serum IgE(261±329)mg·L-1.Conclusion: The combined treatment of Siqikang(BCG-PSN) and SIT can not only effectively reduce the the inflammatory factors in body of bronchial asthmatic patients during the remission stage,but also have faster effectiveness.

     

/

返回文章
返回